US to Pay Pfizer Nearly $2B for More Paxlovid Courses in 2023
Wednesday, December 14, 2022 | Tag Cloud Tags: covid-19, Pfizer | Learn about our FREE SYNDICATION Service | Sign up for our Worthy Briefs! | Printer Friendly
(Worthy News) – The U.S. government agreed to pay Pfizer Inc nearly $2 billion for an additional 3.7 million courses of its COVID-19 antiviral treatment Paxlovid, the company said on Tuesday.
The new purchase supplements the 20 million courses previously bought by the United States and are planned for delivery by early 2023, Pfizer said in a statement.
The Biden administration had previously agreed to pay around $10.6 billion – roughly $530 per treatment course – for the first 20 million courses it ordered. They are paying around the same amount per course under the new contract. [ Source: Newsmax (Read More…) ]
Fair Use Notice:This site contains copyrighted material the use of which has not always been specifically authorized by the copyright owner. We are making such material available in our efforts to advance understanding of environmental, political, human rights, economic, democracy, scientific, and social justice issues, etc. We believe this constitutes a 'fair use' of any such copyrighted material as provided for in section 107 of the US Copyright Law. In accordance with Title 17 U.S.C. Section 107, the material on this site is distributed without profit to those who have expressed a prior interest in receiving the included information for research and educational purposes. For more information go to: http://www.law.cornell.edu/uscode/17/107.shtml. If you wish to use copyrighted material from this site for purposes of your own that go beyond 'fair use', you must obtain permission from the copyright owner.